Post-Hoc Analysis Confirms Consistent Clinical Benefit With Olaparib Plus Abiraterone in HRR-Mutated mCRPC
Olaparib plus abiraterone acetate delayed disease progression and improved outcomes in patients with BRCA-, ATM- and CDK12-mutated mCRPC.
Stay updated with breaking news from Cmt Group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Olaparib plus abiraterone acetate delayed disease progression and improved outcomes in patients with BRCA-, ATM- and CDK12-mutated mCRPC.
Telecom operator e& has reported revenue of AED 52.4 billion (+4.7 percent) and net profit of AED 10 billion (+7.4 percent) in 2022.
E& on Monday posted a record 7.4 per cent growth in consolidated net profit to Dh10 billion in 2022 while revenues rose 4.7 per cent to Dh52.4 billion as t..
Amber Grid starts reconstruction of sections of Vilnius-Kaunas gas pipeline, one of the most important Lithuanian gas transmission arteries.
Global Biospecimen Contract Research Services Market Research Report 2022